Familial pituitary tumor syndromes

Nature Reviews Endocrinology

Volumn 5, Issue 8, 2009, Pages 453-461

  Elston, Marianne S ^a   McDonald, Kerrie L ^a   Clifton Bligh, Roderick J ^a   Robinson, Bruce G ^a  

^a UNIVERSITY OF SYDNEY   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

ARYL HYDROCARBON RECEPTOR INTERACTING PROTEIN; BONE MORPHOGENETIC PROTEIN 2; CORTICOTROPIN; CYCLIN DEPENDENT KINASE INHIBITOR 1B; FANCONI ANEMIA GROUP D2 PROTEIN; FORKHEAD BOX PROTEIN N3; FORKHEAD TRANSCRIPTION FACTOR; GLIAL FIBRILLARY ACIDIC PROTEIN; GROWTH HORMONE; HOMEOBOX PROTEIN RHOX 5; HOMEODOMAIN PROTEIN; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; METHIONINE; MULTIPLE ENDOCRINE NEOPLASIA TYPE 1 PROTEIN; PROLACTIN; REPLICATION FACTOR A; REPLICATION FACTOR A PROTEIN 2; SMAD3 PROTEIN; SOMATOMEDIN C; SOMATOSTATIN DERIVATIVE; TRANSCRIPTION FACTOR AP 1; TRANSCRIPTION FACTOR JUND; TUMOR SUPPRESSOR PROTEIN; UNCLASSIFIED DRUG; VIMENTIN;

ACROMEGALY; ADENOMA; CARNEY COMPLEX; CLINICAL FEATURE; CUSHING SYNDROME; DIFFERENTIAL DIAGNOSIS; DISEASE ASSOCIATION; FRAMESHIFT MUTATION; GENE EXPRESSION; GENE FREQUENCY; GENE IDENTIFICATION; GENE LOCUS; GENETIC ASSOCIATION; GENETIC VARIABILITY; GENOTYPE PHENOTYPE CORRELATION; GERM LINE; HETEROZYGOTE; HORMONE RELEASE; HUMAN; HYPERPARATHYROIDISM; HYPOPHYSIS ADENOMA; HYPOPHYSIS TUMOR; MISSENSE MUTATION; MOLECULAR MECHANICS; MULTIPLE ENDOCRINE NEOPLASIA; MULTIPLE ENDOCRINE NEOPLASIA TYPE 4; MUTATIONAL ANALYSIS; MYXOMA; NEURINOMA; NONHUMAN; NONSENSE MUTATION; PANCREAS ISLET CELL TUMOR; PARATHYROID TUMOR; PRIORITY JOURNAL; PROLACTIN BLOOD LEVEL; PROLACTINOMA; PROTEIN EXPRESSION; PROTEIN PROTEIN INTERACTION; REVIEW; TRANSCRIPTION REGULATION; TUMOR MODEL; TUMOR SUPPRESSOR GENE;

CYCLIC AMP-DEPENDENT PROTEIN KINASE RIALPHA SUBUNIT; GENETIC PREDISPOSITION TO DISEASE; HUMANS; INTRACELLULAR SIGNALING PEPTIDES AND PROTEINS; MULTIPLE ENDOCRINE NEOPLASIA; PITUITARY NEOPLASMS; PROTO-ONCOGENE PROTEINS; SYNDROME;

EID: 70349200933     PISSN: 17595029     EISSN: 17595037     Source Type: Journal    
DOI: 10.1038/nrendo.2009.126     Document Type: Review

References (106)

1. Daly, A. F. et al. High prevalence of pituitary adenomas: a cross-sectional study in the province of Liege, Belgium. J. Clin. Endocrinol. Metab. 91,4769-4775 (2006).
2. Ezzat, S. et al. The prevalence of pituitary adenomas: a systematic review. Cancer 101, 613-619 (2004).
3. Scheithauer, B. W. et al. Pituitary adenomas of the multiple endocrine neoplasia type I syndrome. Semin. Diagn. Pathol. 4,205-211 (1987).
4. Chandrasekharappa, S. C. et al. Positional cloning of the gene for multiple endocrine neoplasia-type 1. Science 276,404-407 (1997).
5. Larsson, C. et al. Multiple endocrine neoplasia type 1 gene maps to chromosome 11 and is lost in insulinoma. Nature 332,85-87 (1988).
6. Brandi.M. L et al. Guidelines for diagnosis and therapy of MEN type 1 and type 2. J. Clin. Endocrinol. Metab. 86,5658-5671 (2001).
7. Lemos, M. C. & Thakker, R. V. Multiple endocrine neoplasia type 1 (MEN1): analysis of 1336 mutations reported in the first decade following identification of the gene. Hum. Mutat. 29, 22-32 (2008).
8. Knudson, A. G. Jr. Mutation and cancer: statistical study of retinoblastoma. Proc. Natl Acad. Sci. USA 68,820-823 (1971).
9. Thakker, R. V. et al. Association of parathyroid nefor in multiple endocrine neoplasia type 1 with loss of alleles on chromosome 11. N. Engl. J. Med. 321,218-224 (1989).
10. Friedman, E. et al. Clonality of parathyroid tumors in familial multiple endocrine neoplasia type 1. N. Engl. J. Med. 321,213-218 (1989).
11. Bystrom.C. et al. Localization of the MEN1 gene to a small region within chromosome Ilql3 by deletion mapping in tumors. Proc. Natl Acad. Sci. USA 87,1968-1972 (1990).
12. Pannett, A. A. & Thakker, R. V. Somatic mutations in MEN type 1 tumors, consistent with the Knudson "two-hit" hypothesis. J. Clin. Endocrinol. Metab. 86, 4371-4374 (2001).
13. Benson, L,Ljunghall,S.,Akerstr6m,G. & Oberg, K. Hyperparathyroidism presenting as the first En g l. endocrine neoplasia type 1. Am.J. Med. 82,731-737 (1987).
14. Trump, D. et al. Clinical studies of multiple endocrine neoplasia type 1 (MEN1). QJM 89, 653-669 (1996).
15. Vierimaa, 0. et al. Multiple endocrine neoplasia type 1 in Northern Finland; clinical features and genotype phenotype correlation. Eur.J. Endocrinol. 157,285-294 (2007).
16. Skogseid, B. et al. Multiple endocrine neoplasia type 1: a 10-year prospective screening study in four kindreds. J. Clin. Endocrinol. Metab. 73, 281-287 (1991).
17. Hao, W. et al. Multiple endocrine neoplasia type 1 variant with frequent prolactinoma and rare gastrinoma. J. Clin. Endocrinol. Metab. 89, 3776-3784 (2004).
18. Carty, S. E. et al. The variable penetrance and spectrum of manifestations of multiple endocrine neoplasia type 1. Surgery 124, 1106-1113 (1998).
19. Verges, B. et al. Pituitary disease in MEN type 1 (MEN1): data from the France-Belgium MEN1 multicenter study. J. Clin. Endocrinol. Metab. 87, 457-465 (2002).
20. Machens, A. et al. Age-related penetrance of endocrine tumours in multiple endocrine neoplasia type 1 (MEN1): a multicentre study of 258 gene carriers. Clin. Endocrinol. (Oxf.) 67, 613-622 (2007).
21. Skogseid, B. et al. Clinical and genetic features of adrenocortical lesions in multiple endocrine neoplasia type 1. J. Clin. Endocrinol. Metab. 75, 76-81 (1992).
22. Schussheim, D. H. et al. Multiple endocrine neoplasia type 1: new clinical and basic findings. Trends Endocrinol. Metab. 12,173-178 (2001).
23. Darling, N. et al. Multiple facial angiofibromas and collagenomas in patients with multiple endocrine neoplasia type 1. Arch. Dermatol. 133, 853-857 (1997).
24. Stratakis,C. A. et al. Pituitary macroadenoma in a 5-year-old: an early expression of multiple endocrine neoplasia type 1. J. Clin. Endocrinol. Metab. 85,4776-4780 (2000).
25. O'Brien,T. et al. Results of treatment of pituitary hyperplasia in multiple endocrine neoplasia type I. Neurosurgery 39,273-278 (1996).
26. Trouillas,J. et al. Pituitary tumors and hyperplasia in multiple endocrine neoplasia type 1 syndrome (MEN1): a case-control study in a series of 77 patients versus 2509 non-MEN1 patients. Am. J. Surg. Patriot. 32,534-543 (2008).
27. Corbetta, S. et al. Multiple endocrine neoplasia type 1 in patients with recognized pituitary tumours of different types. Clin. Endocrinol. (Oxf.) 47, 507-512 (1997).
28. Scheithauer, B. W. et al. Multiple endocrine neoplasia type 1-associated thyrotropin-producing pituitary carcinoma: report of a probable de novo example. Hum. Pathol. 40, 270-280 (2009).
29. Gordon, M. V. et al. Metastatic prolactinoma presenting as a cervical spinal cord tumour in multiple endocrine neoplasia type one (MEN-1). Clin. Endocrinol. (Oxf.) 66,150-152 (2007).
30. Liu S. W.,vandeVelde,C. J.,Heslinga, J. M., Kievit, J. & Roelfsema, F. Acromegaly caused by growth hormone-releasing hormone in a patient with multiple endocrine neoplasia type I. Jpn J. Clin. Oncol. 26,49-52 (1996).
31. Ramsay, J. A., Kovacs, K., Asa, S. L.Pike, M. J. Thorner, M. 0. Reversible sellar enlargement due to growth hormone-releasing hormone production by pancreatic endocrine tumors in a acromegalic patient with multiple endocrine neoplasia type I syndrome. Cancer 62,445-450 (1988).
32. Wautot, V. et al. Germline mutation profile of MEN1 in multiple endocrine neoplasia type 1: search for correlation between phenotype and the functional domains of the MEN1 protein. Hum. Mutat. 20,35-47 (2002).
33. Burgess, J. R., Shepherd, J. J.,Parameswaran, V, Hoffman, L. & Greenaway,T. M. Spectrum of pituitary disease in multiple endocrine neoplasia type 1 (MEN 1): clinical, biochemical, and radiological features of pituitary disease in a large MEN 1 kindred. J. Clin. Endocrinol. Metab. 81,2642-2646 (1996).
34. Olufemi, S. E. et al. Common ancestral mutation in the MEN1 gene is likely responsible for the prolactinoma variant of MEN1 (MENlBurin) in four kindreds from Newfoundland. Hum. Mutat. 11, 264-269 (1998).
35. Petty, E. M. et al. Mapping the gene for hereditary hyperparathyroidism and prolactinoma (MENlBurln) to chromosome llq: evidence for a founder effect in patients from Newfoundland. Am. Hum. Genet. 54,1060-1066 (1994).
36. Burgess, J. R. et al. Phenotype and phenocopy: the relationship between genotype and clinical phenotype in a single large family with multiple endocrine neoplasia, type 1, devel 1). Clin. Endocrinol. (Oxf.) 53,205-211 (2000).
37. Crabtree, J. S. et al. A mouse model of multiple endocrine neoplasia, type 1, develops multiple endocrine tumors. Proc. NatlAcad. Sci. USA 98, 1118-1123 (2001).
38. Biondi, C. A. et al. Conditional inactivation of the MEN1 gene leads to pancreatic and pituitary tumorigenesis but does not affect normal development of these tissues. Mol. Cell Biol. 24, 3125-3131 (2004).
39. Bertolino.P, Tong.W. M.,Galendo, D., Wang, Z. Q. & Zhang, C. X. Heterozygous Menl mutant mice develop a range of endocrine tumors mimicking multiple endocrine neoplasia type 1. Mol. Endocrinol. 17,1880-1892 (2003).
40. Pannett, A. A. et al. Multiple endocrine neoplasia type 1 (MEN1) germline mutations in familial isolated primary hyperparathyroidism. Clin. Endocrinol. (Oxf.) 58,639-646 (2003).
41. Guru.S. C. et al. Menin, the product of the MEN1 gene, is a nuclear protein. Proc. NatlAcad. Sci. USA 95,1630-1634 (1998).
42. La, P et al. Tumor suppressor menin: the essential role of nuclear localization signal domains in coordinating gene expression. Oncogene 25,3537-3546 (2006).
43. Yang.Y. & Hua.X. In search of tumor suppressing functions of menin. Mol. Cell Endocrinol. 265-266,34-41 (2007).
44. Dreijerink, K. M.,Hoppener,J. W.,Timmers, H. M. & Lips, C. J. Mechanisms of disease: multiple endocrine neoplasia type 1-relation to chromatin modifications and transcription regulation. Nat. Clin. Pract. Endocrinol. Metab. 2, 562-570 (2006).
45. Scacheri, PC. et al. Genome-wide analysis of menin binding provides insights into MEN1 tumorigenesis. PLoS Genet. 2, e51 (2006).
46. Karnik, S. K. et al. Menin regulates pancreatic islet growth by promoting histone methylation and expression of genes encoding p27Kipl and pl8INK4c. Proc. NatlAcad. Sci. USA 102, 14659-14664 (2005).
47. Milne,T. A. et al. Menin and MLLcooperatively regulate expression of cyclin-dependent kinase inhibitors. Proc. NatMcad.Sc/. USA 102, 749-754 (2005).
48. Hughes, C. M. et al. Menin associates with a trithorax family histone methyltransferase complex and with the Hoxc8 locus. Mo/. Cell 13, 5-47 (2002).
49. Franklin, D. S., Godfrey, V. L, O'Brien, D. A., Deng, C. & Xiong, Y. Functional collaboration between different cyclin-dependent kinase inhibitors suppresses tumor growth with distinct tissue specificity. Mo/. Cell Biol. 20,6147-6158 (2000).
50. Stalberg, P et al. Transfection of the multiple endocrine neoplasia type 1 gene to a human endocrine pancreatic tumor cell line inhibits cell growth and affects expression of JunD, delta-like protein 1/preadipocyte factor-1, proliferating cell nuclear antigen, and QM/Jif-1. J. Clin. Endocrinol. Metab. 89,2326-2337 (2004).
51. Kim, Y. S. et al. Stable overexpression of MEN1 suppresses tumorigenicity of Ras. Oncogene 18, 5936-5942 (1999).
52. Lin, S. Y. & Elledge, S. J. Multiple tumor suppressor pathways negatively regulate telomerase. Cell 113,881-889 (2003).
53. Ellard, S., Hattersley, A. T, Brewer, C. M. & Vaidya, B. Detection of an MEN1 gene mutation depends on clinical features and supports current referral criteria for diagnostic molecular genetic testing. Clin. Endocrinol. (Oxf.) 62, 169-175 (2005).
54. Tham, E. et al. Clinical testing for mutations in the MEN1 gene in Sweden: a report on 200 unrelated cases. J. Clin. Endocrinol. Metab. 92, 3389-3395 (2007).
55. Ozawa, A. et al. The parathyroid/pituitary variant of multiple endocrine neoplasia type 1 usually has causes other than p27Kipl mutations. J. Clin. Endocrinol. Metab. 92,1948-1951 (2007).
56. Hai, N.,Aoki,N.,Matsuda,A.,Mori,T. & Kosugi, S. Germline MEN1 mutations in sixteen Japanese families with multiple endocrine neoplasia type 1 (MEN1). Eur.J. Endocrinol. 141, 475-480 (1999).
57. Hai, N. & Kosugi, S. Gene diagnosis and clinical management of multiple endocrine neoplasia type 1 (MEN1). Biomed. Pharmacother. 54 (Suppl. 1), S47-S51 (2000).
58. Tortosa, F. et al. Prevalence of MEN 1 in patients with prolactinoma. MEN1 Study Group of the Hospital de la Santa Creu i Sant Pau of Barcelona. Clin. Endocrinol. (Oxf.) 50,272 (1999).
59. Klein, R. D.,Salih,S., Bessoni J. & Bale, A. E. Clinical testing for multiple endocrine neoplasia type 1 in a DNA diagnostic laboratory. Genet. Med. 7,131-138 (2005).
60. Georgitsi, M. et al. Germline CDKN1B/p27Ki1 p1cause a multiple endocrine neoplasia J. Clin. Endocrinol. Metab. 92,3321-3325 (2007).
61. Pellegata, N. S. et al. Germ-line mutations in p27Kiplcause a multiple endocrine neoplasia syndrome in rats and humans. Proc. NatlAcad. Sci. USA 103,15558-15563 (2006).
62. dhar,K. et al. Low and expression analysis of the p27/kipl gene in corticotrophin-secreting tumours. Oncogene 16,69-76 (1998).
63. Lidhar, K. et al. Low expression of the cell cycle inhibitor p27wpl in normal corticotroph cells, corticotroph tumors, and malignant pituitary tumors. J. Clin. Endocrinol. Metab. 84, 3823-3830 (1999).
64. Jin, L. et al. Transforming growth factor-p, transforming growth factor- p receptor II, and p27Kipl expression in nontumorous and neoplastic human pituitaries. Am.J. Pathol. 151, 509-519 (1997).
65. Kolluri, S. K., Weiss, C, Koff, A. & Gottlicher, M. p27Kipl induction and inhibition of proliferation by the intracellularAh receptor in developing thymus and hepatoma cells. Genes Dev. 13, 1742-1753 (1999).
66. Kiyokawa, H. et al. Enhanced growth of mice lacking the cyclin-dependent kinase inhibitor function of p27Kipl. Cell 85, 721-732 (1996).
67. Fero,M. L. et al. A syndrome of multiorgan hyperplasia with features of gigantism, tumorigenesis, and female sterility in p27(Kip1)-deficient mice. Cell 85, 733-744 (1996).
68. Nakayama, K. et al. Mice lacking p27Kpl display increased body size, multiple organ hyperplasia, retinal dysplasia,and pituitary tumors. Cell 85, 707-720 (1996).
69. Besson, A. et al. Discovery of an oncogenic activity in p27Kipl that causes stem cell expansion and a multiple tumor phenotype. Genes Dev. 21,1731-1746 (2007).
70. Carney, J. A., Gordon, H., Carpenter, PC, Shenoy, B. V. & Go, V. L. The complex of myxomas, spotty pigmentation, and endocrine overactivity. Medicine (Baltimore) 64,270-283 (1985).
71. Schweizer-Cagianut, M., Salomon, F. & Hedinger, C. E. Primary adrenocortical nodular dysplasia with Cushing's syndrome and cardiac myxomas. A peculiar familial disease. Virchows Arch. A Pathol.Anat Histol. 397,183-192 (1982).
72. Boikos, S. A. & Stratakis, C. A. Carney complex: the first 20 years. Curr. Opin. Oncol. 19,24-29 (2007).
73. Carney, J. A. & Toorkey, B. C. Ductal adenoma of the breast with tubular features. A probable component of the complex of myxomas, spotty pigmentation, endocrine overactivity, and schwannomas. Am. J. Surg. Pathol. 15,722-731 (1991).
74. Basson, C. T., MacRae, C. A., Korf, B. & Merliss, A. Genetic heterogeneity of familial atrial myxoma syndromes (Carney complex). Am.J. Cardiol. 79,994-995 (1997).
75. Boikos, S. A. & Stratakis, C. A. Carney complex: pathology and molecular genetics. Neuroendocrinology 83,189-199 (2006).
76. Stratakis, C. A. et al. Carney complex, a familial multiple neoplasia and lentiginosis syndrome. Analysis of 11 kindreds and linkage to the short arm of chromosome 2. J. Clin. Invest. 97, 699-705 (1996).
77. Kirschner, L. S. et al. Mutations of the gene encoding the protein kinase A type l-a regulatory subunit in patients with the Carney complex. Nat. Genet. 26,89-92 (2000).
78. Horvath, A. & Stratakis, C. A. Clinical and molecular genetics of acromegaly: MEN1, Carney complex, McCune-Albright syndrome, familial acromegaly and genetic defects in sporadic tumors. Rev. Endocr. Metab. Disord. 9,1-11 (2000).
79. Watson, J. C. et al. Neurosurgical implications of Carney complex. J. Neurosurg. 92,413-418 (2000).
80. Pack, S. D. et al. Genetic and histologic studies of somatomammotropic pituitary tumors in patients with the "complex of spotty skin pigmentation, myxomas, endocrine overactivity and schwannomas" (Carney complex). J. Clin. Endocrinol. Metab. 85,3860-3865 (2000).
81. Boikos, S. A. & Stratakis, C. A. Pituitary pathology in patients with Carney complex: growth-hormone producing hyperplasia or tumors and ter actions with other abnormalities. Pituitary 9,203-209 (2006).
82. Robinson-White, A. et al. PRKAR1A Mutations and protein kinase A interactions with other signaling pathways in the adrenal cortex. J. Clin. Endocrinol. Metab. 91,2380-2388 (2006).
83. Kirschner, L. S. et al. A mouse model for the Carney complex tumor syndrome develops neoplasia in cyclic AMP-responsive tissues. Cancer Res. 65,4506-4514 (2005).
84. Griffin, K. J. et al. A mouse model for Carney complex. Endocr. Res. 30,903-911 (2004).
85. Yin, Z., Williams-Simons, L.Parlow, A. F.,Asa, S. & Kirschner, L. S. Pituitary-specific knockout of the Carney complex gene Prkarla leads to pituitary tumorigenesis. Mo/. Endocrinol. 22, 380-387 (2008).
86. Beckers, A. & Daly, A. F. The clinical, pathological, and genetic features of familial isolated pituitary adenomas. Eur. J. Endocrinol. 157,371-382 (2007).
87. Vierimaa, 0. et al. Pituitary adenoma predisposition caused by germline mutations in the AIP gene. Science 312,1228-1230 (2006).
88. Leontiou.C. A. et al. The role of thearyl hydrocarbon receptor-interacting protein gene in familial and sporadic pituitary adenomas. J. Clin. Endocrinol. Metab. 93,2390-2401 (2008).
89. Naves, L A. et al. Variable pathological and clinical features of a large Brazilian family 90.iw a mutation in The aryl hydrocarbon rome.interacting protein gene. Eur. in Endocrinol. 157,383-391 (2007).
90. Iwata, T. et al. The aryl hydrocarbon receptor-interacting protein gene is rarely mutated in sporadic GH-secreting adenomas. Clin. Endocrinol. (Oxf.) 66,499-502 (2007).
91. Toledo, R. A. et al. Germline mutation in the aryl hydrocarbon receptor interacting protein gene in familial somatotropinoma. J. Clin. Endocrinol. Metab. 92,1934-1937 (2007).
92. Daly, A. F. et al. Aryl hydrocarbon receptor-interacting protein gene mutations in familial isolated pituitary adenomas: analysis in 73 families. J. Clin. Endocrinol. Metab. 92, 1891-1896 (2007).
93. Georgitsi, M. et al. Large genomic deletions in AIP ). pituitary adenoma predisposition. J. Clin. Endocrinol. Metab. 93,4146-4151 (2008).
94. Georgitsi, M. et al. Molecular diagnosis of pituitary adenoma predisposition caused by aryl hydrocarbon receptor-interacting protein gene mutations. Proc. NatlAcad. Sci. USA 104, 860-3865 (2000).
95. Buchbinder, S. et al. Aryl hydrocarbon receptor interacting protein gene (AIP) mutations are rare in patients with hormone secreting or non- secreting pituitary adenomas. Exp. Clin. Endocrinol. Diabetes 116,625-628 (2008).
96. Barlier, A. et al. Mutations in the aryl hydrocarbon receptor interacting protein gene are not highly prevalent among subjects with sporadic pituitary adenomas. J. Clin. Endocrinol. Metab. 92,1952-1955 (2007).
97. Cazabat, L et al. Germline inactivating mutations of the aryl hydrocarbon receptor-interacting protein gene in a large cohort of sporadic acromegaly: mutations are found in a subset of young patients with macroadenomas. Eur. J. Endocrinol. 157,1-8 (2007).
98. Raitila, A. et al. No evidence of somatic aryl hydrocarbon receptor interacting protein mutations in sporadic endocrine neoplasia. Endocr. Relat. Cancer 14,901-906 (2007).
99. DiGiovanni, R.,Serra,S., Ezzat, S. Asa,S. L. AIP mutations are not identified in patients with sporadic pituitary adenomas. Endocr. Pathol. 18, 71-382 (2007).
100. Yu, R., Bonert, V., Saporta, I., Raffel, L J. & Melmed, S. Aryl hydrocarbon receptor interacting protein variants in sporadic pituitary adenomas. J. Clin. Endocrinol. Metab. 91,5126-5129 (2006).
101. Georgitsi, M. et al. Aryl hydrocarbon receptor interacting protein (AIP) gene mutation analysis in children and adolescents with sporadic pituitary adenomas. Clin. Endocrinol. (Oxf.) 69, 621-627 (2008).
102. Igreja, S. et al. Assessment of p27 (cyclin-dependent kinase inhibitor IB) and AIP (aryl hydrocarbon receptor-interacting protein) genes in MEN1 syndrome patients without any detectable MEN1 gene mutations. Clin. Endocrinol. (Oxf.) 70,259-264 (2009).
103. Barouki, R., Coumoul, X. & Fernandez-Salguero, P M. The aryl hydrocarbon receptor, more than a xenobiotic-interacting protein. FEBS Lett. 581,3608-3615 (2007).
104. Lees, M. J., Peet.D. J. & Whitelaw, M. L. Defining the role forXAP2 in stabilization of the dioxin receptor. J. Biol. Chem. 278,35878-35888 (2003).
105. Ge, N. L. & Elferink.C. J. A direct interaction between the aryl hydrocarbon receptor and retinoblastoma protein. Linking dioxin signaling to the cell cycle. J. Biol. Chem. 273, 22708-22713 (1998).
106. Bolger, G. B. et al. Attenuation of the activity of the cAMP-specific phosphodiesterase PDE4A5 by interaction with the immunophilin XAP2. J. Biol. Chem. 278,33351-33363 (2003).